CEPI and Samsung Biologics partner to boost global vaccine preparedness

With a budget of up to $20m, the collaboration will establish scalable, rapid manufacturing for recombinant-protein vaccines.
Morningstar

GC Biopharma's Recombinant Anthrax Vaccine, BARYTHRAX, Demonstrates Safety and Immunogenicity in Phase 2 Data, Published in 'Vaccine'

YONGIN, South Korea, Nov. 3, 2025 /PRNewswire/ -- GC Biopharma, a leading global pharmaceutical company based in South Korea, announced today that the Phase 2 clinical trial results for its anthrax ...
Medscape

Egg and Non-Egg Flu Shots Appear Comparable in Trial

Egg- and non-egg-based influenza vaccines showed equivalent protection against laboratory-confirmed influenza‑like illness and related hospitalizations among healthy adults in the military health ...
MedPage Today

When It Comes to the Shingles Vaccine, More Is Better

Among older adults who received at least one dose of the recombinant shingles vaccine, vaccine effectiveness against any herpes zoster-related outcome was 56.1%. Getting a second dose yielded a ...
Nasdaq

Vaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology

SOUTH SAN FRANCISCO, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its ...
BioTechniques

Updates on Influenza vaccine strain recommended by WHO (2025–2026 northern hemisphere)

Trivalent egg-based A/Thailand/8/2022 (H3N2) A/Croatia/10136RV/2023 (H3N2) H3N2 strain substituted Trivalent cell/recombinant A/Massachusetts/18/2022 (H3N2) A/District of Columbia/27/2023 (H3N2) H3N2 ...